InnoCare Pharma Limited (INCPF)

OTC Healthcare Biotechnology

InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination wi…